



Ryeqo (Relugolix/Estradiol/Norethisterone) compared to Tranexamic Acid for Symptomatic Uterine Fibroids in Premenopausal Women (20 to 40-year-old): A Cost-utility Analysis

Supplementary Data

Cost Breakdown

<i>Items</i>	<i>Cost</i>	<i>Usage & Unit cost</i>	<i>Source/Details</i>
Ryeqo (6-month treatment)	£ 468.00	£ 72/bottle with 28 tablets One tablet/day *182 (6 months)	BNF(Anon, n.d.a)
DXA scan (for Ryeqo)	£ 63.00	£ 63.00/person	NHS Payment Scheme (NHS Payment Scheme, n.d.)
Prescription Cost	£ 33.00	£ 33.00/person	PSSRU (Anon, n.d.e)
Gynaecology outpatient consultation (2 times)	£ 279.00	£ 174.00/person for the first consultation £ 105.00/person for the follow-up consultation	NHS Payment Scheme – Outpatient (NHS Payment Scheme, n.d.)
Tranexamic Acid (6-month treatment)	£ 24.67	£10.28/bottle with 60 tablets 24 tablets/month	BNF, averaged from all available medicinal forms (Anon, n.d.b)
Cost of Surgery (Myomectomy)	£ 3,024.00	£ 3,024.00/person	NHS Payment Scheme (NHS Payment Scheme, n.d.)
Cost of Surgery (Myomectomy) with complications	£ 3,689.00	£ 3,689.00/person	NHS Payment Scheme (NHS Payment Scheme, n.d.)

Cost Breakdown in All Modelling Scenarios

Scenarios	Cost	Details
Ryeqo (Response)	£ 1,311.00	Drug price (1 year) + prescription cost, 2 times GYN opt consultation, DXA Scan
Ryeqo: Non-responsive, surgery Comp	£ 4,532.00	Drug price (6 month) + prescription cost, 2 times GYN opt consultation, TVA USG, DXA Scan, cost of surgery with complication
Ryeqo: Non-responsive, surgery with no complications	£ 3,867.00	Drug price (6 month) + prescription cost, 2 times GYN opt consultation, TVA USG, DXA Scan, cost of surgery without complication
TXA (Response)	£ 361.34	Drug price (1 year) + prescription cost, 2 times GYN opt consultation
TXA: Nonresponsive, surgery complication	£ 4,025.67	Drug price (6 month) + prescription cost, 2 times GYN opt consultation, cost of surgery with complication
TXA: Nonresponsive, surgery with no comp	£ 3,360.67	Drug price (6 month) + prescription cost, 2 times GYN opt consultation, cost of surgery without complication

Utility Values

Case	Utility	Source
Base case utility	0.69	(Cruickshank, 2022)
Relugolix CT + 6 month	0.81	(Richter, n.d.)
Myomectomy successful	0.91	(Cain-Nielsen et al., 2014)
Myomectomy unsuccessful	0.73	(Cain-Nielsen et al., 2014)
TXA + 6 month	0.76	(Cruickshank, 2022)

QALYs breakdown

<i>Utilities</i>	<i>Baseline</i>	<i>6-month</i>	<i>12-month</i>	<i>QALYs 0-6</i>	<i>QALYs 6-12</i>	<i>QALYs combined</i>
Ryeqo: Response	0.69	0.81	0.81	0.37	0.41	0.78
Ryeqo: NR, surgery complication	0.69	0.69	0.73	0.34	0.35	0.70
Ryeqo: NR, surgery no complication	0.69	0.69	0.91	0.34	0.40	0.74
TXA: response	0.69	0.76	0.76	0.36	0.38	0.75
TXA: NR, surgery complication	0.69	0.69	0.73	0.34	0.35	0.70
TXA: NR, surgery no complication	0.69	0.69	0.91	0.34	0.40	0.74

Sensitivity Analysis – Value Range

	<i>Parameters</i>	<i>Lower value</i>	<i>Base-case value</i>	<i>Upper value</i>
Probabilities	Probability of Ryeqo	0.71	0.72	0.73
	Probability of TXA	0.35	0.39	0.43
Utilities	State of Ryeqo	0.69	0.77	0.91
	State of TXA	0.69	0.74	0.91
Costs	Cost of Ryeqo	1311.00	2041.58	4532.00
	Cost of TXA	361.34	2223.38	4025.67

Base Case Results

	<i>TXA</i>	<i>Ryeqo</i>	<i>Difference</i>
Costs	£2,223.38	£2,041.58	-£181.81
QALYs	0.74	0.77	0.03
ICER			-£6,904.92
Net monetary benefit (NMB)			Incremental MB
Lower (£20.000)	12,627.49	13,335.90	£708.41
Upper (£30.000)	20052.92	21,024.63	£971.71
Net health benefit (NHB)			Incremental HB
Lower (£20.000)	0.63	0.67	0.04
Upper (£30.000)	0.67	0.70	0.03

Univariate Sensitivity Analysis Results

ICER	Lower ICER	Higher ICER
Costs of Ryeqo	-26355.80	66688.45
Costs of TXA	48536.57	-57314.04
Probability of Ryeqo	16844.38	18025.16
Probability of TXA	2303.79	13877.19
Utility of Ryeqo	3297.13	-1102.80
Utility of TXA	-2025.51	1395.93
ICER base case	-£6,904.92	

References

- Al-Hendy, A., Lukes, A.S., Poindexter, A.N., Venturella, R., Villarroel, C., Critchley, H.O.D., Li, Y., McKain, L., Arjona Ferreira, J.C., Langenberg, A.G.M., Wagman, R.B. & Stewart, E.A. (2021) Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy. *The New England journal of medicine*. 384 (7), 630–642. doi:10.1056/NEJMoa2008283.
- Al-Hendy, A., Venturella, R., Arjona Ferreira, J.C., Li, Y., Soulban, G., Wagman, R.B. & Lukes, A.S. (2023) LIBERTY randomized withdrawal study: relugolix combination therapy for heavy menstrual bleeding associated with uterine fibroids. *American journal of obstetrics and gynecology*. 229 (6), 662.e1-662.e25. doi:10.1016/j.ajog.2023.08.030.
- Arjona Ferreira, J.C. & Migoya, E. (2023) Development of relugolix combination therapy as a medical treatment option for women with uterine fibroids or endometriosis. *F&S Reports (Online)*. 4 (2), 73–82. doi:10.1016/j.xfre.2022.11.010.
- Bradley, L.D. & Gueye, N.-A. (2016) The medical management of abnormal uterine bleeding in reproductive-aged women. *American journal of obstetrics and gynecology*. 214 (1), 31–44. doi:10.1016/j.ajog.2015.07.044.
- Cardozo, E.R., Clark, A.D., Banks, N.K., Henne, M.B., Stegmann, B.J., & Segars, J.H. (2012) The Estimated Annual Cost of Uterine Leiomyomata in the United States. *American Journal of Obstetrics and Gynecology*, 206(3), 211.e1-211.e9.
- Chauncey, J.M. & Wieters, J.S. (2023) *Tranexamic Acid*. 24 July 2023. Nih.gov. <https://www.ncbi.nlm.nih.gov/books/NBK532909/> [Accessed: 12 March 2024].
- ElKafas, H., Ali, M. & Al-Hendy, A. (2018) Leiomyomas. In *Encyclopedia of Reproduction*. <https://doi.org/10.1016/B978-0-12-801238-3.64527-0>

References (cont.)

- Guo, X. C., & Segars, J. H. (2012) The impact and management of fibroids for fertility: an evidence-based approach. *Obstetrics and gynecology clinics of North America*, 39(4), 521–533. <https://doi.org/10.1016/j.ogc.2012.09.005>
- Kashani, B.N., Centini, G., Morelli, S.S., Weiss, G. & Petraglia, F. (2016) Role of Medical Management for Uterine Leiomyomas. *Best practice & research. Clinical obstetrics & gynaecology*. 34, 85–103. doi:10.1016/j.bpobgyn.2015.11.016.
- King, R., & Overton, C. (2011) Management of fibroids should be tailored to the patient. *The Practitioner*, 255(1738), 19–3.
- Landau-Taylor, J., McGivney, C. & Christiansen, A. (2022) Access to Care After Autism Diagnosis During the COVID-19 Pandemic: A Quality Improvement Project. *Journal of Developmental and Behavioral Pediatrics*. 44 (2), e73–e79. doi:<https://doi.org/10.1097/dbp.0000000000001146>
- Leminen, H. & Hurskainen, R. (2012) Tranexamic acid for the treatment of heavy menstrual bleeding: efficacy and safety. *International Journal of Women's Health*. 413–413. doi:<https://doi.org/10.2147/ijwh.s13840>.
- Martín-Merino, E., Wallander, M. A., Andersson, S., Soriano-Gabarró, M., & Rodríguez, L. A. (2016) The reporting and diagnosis of uterine fibroids in the UK: an observational study. *BMC women's health*, 16, 45. <https://doi.org/10.1186/s12905-016-0320-8>
- Meaidi, A., Mørch, L., Torp-Pedersen, C., & Lidegaard, O. (2021) Oral tranexamic acid and thrombosis risk in women. *EClinicalMedicine*, 35, 100882. <https://doi.org/10.1016/j.eclinm.2021.100882>
- Medicines & Healthcare products Regulatory Agency (MHRA). (2021) Public Assessment Report National Procedure – Ryego 40mg/1mg/0.5mg film-coated tablets (relugolix, estradiol and norethisterone acetate) [PLGB 04854/0186]. <https://mhraproducts4853.blob.core.windows.net/docs/9abe13fa253d5cbe8521b96054f95539b4c427fa> [Assessed 19th March 2024]
- National Institute for Health and Care Excellence (NICE). (n.d.) Scenario: Management of fibroids. <https://cks.nice.org.uk/topics/fibroids/management/management/> [Assessed 19th March 2024]

References (cont.)

- National Institute for Health and Care Excellence (NICE). (n.d.) Scenario: Management of menorrhagia (heavy menstrual bleeding). <https://cks.nice.org.uk/topics/menorrhagia-heavy-menstrual-bleeding/management/management/> [Assessed 19th March 2024]
- National Institute for Health and Care Excellence (NICE). (2021) Heavy menstrual bleeding: assessment and management [NG88]. <https://www.nice.org.uk/guidance/ng88/resources/heavy-menstrual-bleeding-assessment-and-management-pdf-1837701412549> [Assessed 19th March 2024]
- Peitsidis, P. & Koukoulomati, A. (2014) Tranexamic acid for the management of uterine fibroid tumors: A systematic review of the current evidence. World journal of clinical cases. 2 (12), 893–898. doi:10.12998/wjcc.v2.i12.893.
- Strong, S.M., Sideris, M., Magama, Z., Rouabhi, S., & Odejinmi, F. (2020) Surgical Intervention for Uterine Fibroids. Our 4-Year Experience and Literature Review: Is It Time to Centralise Care Provision Via Specialist Fibroid Centres? in vivo, 34(3), 695-701.
- Syed, Y.Y. (2022) Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine Fibroids. Drugs (New York, N.Y.). 82 (15), 1549–1556. doi:10.1007/s40265-022-01790-4.
- Anon (n.d.a) *Medicinal forms | Relugolix with estradiol and norethisterone acetate | Drugs | BNF content published by NICE.* <https://bnf.nice.org.uk/drugs/relugolix-with-estradiol-and-norethisterone-acetate/medicinal-forms/> [Accessed: 7 April 2024].
- Anon (n.d.b) *Medicinal forms | Tranexamic acid | Drugs | BNF content published by NICE.* <https://bnf.nice.org.uk/drugs/tranexamic-acid/medicinal-forms/> [Accessed: 7 April 2024].
- Anon (n.d.c) *Position statement on use of the EQ-5D-5L value set for England (updated October 2019) | Technology appraisal guidance | NICE guidance | Our programmes | What we do | About.* NICE. <https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/technology-appraisal-guidance/eq-5d-5l> [Accessed: 7 April 2024].
- Anon (2018) *Recommendations | Heavy menstrual bleeding: assessment and management | Guidance | NICE.* 14 March 2018. <https://www.nice.org.uk/guidance/ng88/chapter/recommendations> [Accessed: 8 April 2024].
- Anon (n.d.d) *Relugolix with estradiol and norethisterone acetate | Drugs | BNF content published by NICE.* <https://bnf.nice.org.uk/drugs/relugolix-with-estradiol-and-norethisterone-acetate/> [Accessed: 8 April 2024].

References (cont.)

- Anon (n.d.e) *Unit Costs of health and Social Care 2022 (amended 13 July 2023).pdf*.
<https://kar.kent.ac.uk/100519/1/Unit%20Costs%20of%20health%20and%20Social%20Care%202022%20%28amended%2013%20July%202023%29.pdf>.
- Cain-Nielsen, A.H., Moriarty, J.P., Stewart, E.A. & Borah, B.J. (2014) Cost-effectiveness of uterine-preserving procedures for the treatment of uterine fibroid symptoms in the USA. *Journal of Comparative Effectiveness Research*. 3 (5), 503–514. doi:10.2217/CER.14.32.
- Cruickshank, M. (2022) *Relugolix with oestradiol and norethisterone acetate for treating uterine fibroids [ID3842]*.
- Cruickshank, M., Jacobsen, E., Vadivaloo, T., Imamura, M., Cooper, D., Manson, P., Cooper, K., Boyers, D. & Brazzelli, M. (2022) *Relugolix with oestradiol and norethisterone acetate for treating uterine fibroids [ID3842]*.
- Haacker, M., Hallett, T.B. & Atun, R. (2020) On time horizons in health economic evaluations. *Health Policy and Planning*. 35 (9), 1237–1243. doi:10.1093/heapol/czaa073.
- National Institute for Health and Care Excellence (NICE) England (2024) *Medicinal forms | Relugolix with estradiol and norethisterone acetate | Drugs | BNF content published by NICE*. 8 April 2024. British National Formulary.
<https://bnf.nice.org.uk/drugs/relugolix-with-estradiol-and-norethisterone-acetate/medicinal-forms/> [Accessed: 8 April 2024].
- National Institute for Health and Care Excellence (NICE) England (2022) *Single Technology Appraisal: Relugolix-estradiol-norethisterone acetate for treating moderate and severe symptoms of uterine fibroids [ID3842] Committee Papers*.
- NHS Payment Scheme (n.d.) https://www.england.nhs.uk/wp-content/uploads/2023/03/23-25NHSPS_Annex-A_2024-25.xlsx.
- Richter, G. (n.d.) *relugolix 40mg, estradiol 1mg, norethisterone acetate 0.5mg film-coated tablets (Ryeqo®)*.
- Scottish Medicines Consortium (SMC) (2022) *Medicines advice: relugolix 40mg, estradiol 1mg, norethisterone acetate 0.5mg film-coated tablets (Ryeqo®)*.